Mobocertinib in non-small cell lung cancer
Copyright 2022 Clarivate..
Tyrosine kinase inhibitors (TKIs) have provided great benefit for patients with EGFR-mutant non-small cell lung cancer (NSCLC). While prior TKIs have demonstrated limited efficacy against exon 20 insertion mutations of EGFR (EGFR Ex20Ins), mobocertinib (TAK-788) is designed to specifically inhibit these Ex20Ins mutations. In a phase I/II clinical trial, mobocertinib demonstrated meaningful benefits among a cohort of platinum-pretreated patients with EGFR Ex20Ins mutant NSCLC. For this cohort, the objective response rate was 28% (95% confidence interval [CI], 20%-37%). The median progression-free survival and duration of response were 7.3 months (95% CI, 5.5-9.2) and 17.5 months (95% CI, 7.4-20.3), respectively, both by independent review committee assessment. On the basis of these results, mobocertinib was granted accelerated approval as the first TKI for treatment of this indication by the U.S. Food and Drug Administration (FDA) in 2021. This review summarizes the preclinical development of mobocertinib and the early-phase clinical data leading to its approval and discusses potential directions for mobocertinib's development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 58(2022), 11 vom: 30. Nov., Seite 523-530 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Shengwu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 29.11.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2022.58.11.3408816 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349355886 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349355886 | ||
| 003 | DE-627 | ||
| 005 | 20231226042425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2022.58.11.3408816 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349355886 | ||
| 035 | |a (NLM)36422513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Shengwu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mobocertinib in non-small cell lung cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 29.11.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2022 Clarivate. | ||
| 520 | |a Tyrosine kinase inhibitors (TKIs) have provided great benefit for patients with EGFR-mutant non-small cell lung cancer (NSCLC). While prior TKIs have demonstrated limited efficacy against exon 20 insertion mutations of EGFR (EGFR Ex20Ins), mobocertinib (TAK-788) is designed to specifically inhibit these Ex20Ins mutations. In a phase I/II clinical trial, mobocertinib demonstrated meaningful benefits among a cohort of platinum-pretreated patients with EGFR Ex20Ins mutant NSCLC. For this cohort, the objective response rate was 28% (95% confidence interval [CI], 20%-37%). The median progression-free survival and duration of response were 7.3 months (95% CI, 5.5-9.2) and 17.5 months (95% CI, 7.4-20.3), respectively, both by independent review committee assessment. On the basis of these results, mobocertinib was granted accelerated approval as the first TKI for treatment of this indication by the U.S. Food and Drug Administration (FDA) in 2021. This review summarizes the preclinical development of mobocertinib and the early-phase clinical data leading to its approval and discusses potential directions for mobocertinib's development | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a EGFR (Ex20Ins mutant) inhibitors | |
| 650 | 4 | |a HER2 (Ex20Ins mutant) inhibitors | |
| 650 | 4 | |a Mobocertinib | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a Solid tumor therapy | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a mobocertinib |2 NLM | |
| 700 | 1 | |a Lowder, Kristen E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 58(2022), 11 vom: 30. Nov., Seite 523-530 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2022 |g number:11 |g day:30 |g month:11 |g pages:523-530 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2022.58.11.3408816 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2022 |e 11 |b 30 |c 11 |h 523-530 | ||